Literature DB >> 24117842

SALL4 immunohistochemistry in non-small-cell lung carcinomas.

Masakazu Fujimoto1, Shinji Sumiyoshi, Akihiko Yoshizawa, Makoto Sonobe, Masashi Kobayashi, Koki Moriyoshi, Aiko Kido, Chiaki Tanaka, Itsuko Koyanagi, Hiroshi Date, Hironori Haga.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24117842     DOI： 10.1111/his.12241

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


× No keyword cloud information.
  11 in total

Review 1.  SALL4, the missing link between stem cells, development and cancer.

Authors:  Hiro Tatetsu; Nikki R Kong; Gao Chong; Giovanni Amabile; Daniel G Tenen; Li Chai
Journal:  Gene       Date:  2016-02-16       Impact factor: 3.688

2.  Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide.

Authors:  Bee Hui Liu; Chacko Jobichen; C S Brian Chia; Tim Hon Man Chan; Jing Ping Tang; Theodora X Y Chung; Jia Li; Anders Poulsen; Alvin W Hung; Xiaoying Koh-Stenta; Yaw Sing Tan; Chandra S Verma; Hong Kee Tan; Chan-Shuo Wu; Feng Li; Jeffrey Hill; Joma Joy; Henry Yang; Li Chai; J Sivaraman; Daniel G Tenen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-05       Impact factor: 11.205

3.  The expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer.

Authors:  Xiangbo Jia; Rulin Qian; Binbin Zhang; Song Zhao
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

4.  Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.

Authors:  Akihiko Yoshida; Eisuke Kobayashi; Takashi Kubo; Makoto Kodaira; Toru Motoi; Noriko Motoi; Kan Yonemori; Yuichiro Ohe; Shun-Ichi Watanabe; Akira Kawai; Takashi Kohno; Hiroshi Kishimoto; Hitoshi Ichikawa; Nobuyoshi Hiraoka
Journal:  Mod Pathol       Date:  2017-03-03       Impact factor: 7.842

5.  Expression pattern of clinically relevant markers in paediatric germ cell- and sex-cord stromal tumours is similar to adult testicular tumours.

Authors:  Christiane Hammershaimb Mosbech; Terje Svingen; John Erik Nielsen; Birgitte Groenkaer Toft; Catherine Rechnitzer; Bodil Laub Petersen; Ewa Rajpert-De Meyts; Christina Engel Hoei-Hansen
Journal:  Virchows Arch       Date:  2014-07-30       Impact factor: 4.064

6.  Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma.

Authors:  Su-xia Han; Jun-lan Wang; Xi-jing Guo; Chen-chen He; Xia Ying; Jin-lu Ma; Yuan-yuan Zhang; Qian Zhao; Qing Zhu
Journal:  J Immunol Res       Date:  2014-04-17       Impact factor: 4.818

7.  Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma.

Authors:  Yun Kyung Jung; Kiseok Jang; Seung Sam Paik; Yong Jin Kwon; Han Jun Kim; Kyeong Geun Lee; Hwon Kyum Park; Dongho Choi
Journal:  Ann Surg Treat Res       Date:  2016-06-30       Impact factor: 1.859

8.  Targeting SALL4 by entinostat in lung cancer.

Authors:  Kol Jia Yong; Ailing Li; Wen-Bin Ou; Clarice Kit Yee Hong; Wenxiu Zhao; Fei Wang; Hiro Tatetsu; Benedict Yan; Lihua Qi; Jonathan A Fletcher; Henry Yang; Ross Soo; Daniel G Tenen; Li Chai
Journal:  Oncotarget       Date:  2016-11-15

9.  Upregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer.

Authors:  Wenjing Du; Lan Ni; Baojun Liu; Ying Wei; Yubao Lv; Sujing Qiang; Jingcheng Dong; Xijun Liu
Journal:  Oncogenesis       Date:  2018-04-25       Impact factor: 7.485

10.  Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma.

Authors:  Umair Ali Khan Saddozai; Fengling Wang; Muhammad Usman Akbar; Lu Zhang; Yang An; Wan Zhu; Longxiang Xie; Yongqiang Li; Xinying Ji; Xiangqian Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.